Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The…
Search results for: hospital

ARHP Clinical Focus Course Targets Management of Adults with SLE
This year the ARHP Clinical Focus Course brings together experts in the field to provide an interprofessional approach to the management of systematic lupus erythematosus (SLE) to improve patient outcomes. The daylong course, titled Systemic Lupus Erythematosus: Taming the Wolf—Salient Lessons from Practice and Research, which is offered on Nov. 4, will provide a case-based…

The ACR Board of Directors Adopts 5-Year Strategic Plan
Rheumatology is at a critical juncture in our history. To advance into the future, the ACR must thoroughly prepare for changing political landscapes, emerging technologies and workforce challenges. On May 12, the ACR Board of Directors met in Washington, D.C., to approve our ambitious new Strategic Plan for 2017–2022. This plan encompasses five strategic themes…

How Global Geographic Disparities Affect Healthcare Outcomes
Your home & your health: Does geography impact medicine? Does it matter whether a region is surrounded by large bodies of water, encircled by towering mountain peaks or that its residents share a common ancestry? Consider Switzerland, a nation with a highly developed economy replete with advanced technological and medical infrastructure. Despite these advantages, less…

A Stiff Man: A Case Study in Ankylosing Spondylitis
First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…

Opana ER Pulled from U.S. Market
Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.

Upadacitinib Meets Study Endpoints to Treat RA
A recent clinical trial found that upadacitinib may effectively reduce disease activity at Week 12 for patients with moderate to severe rheumatoid arthritis…
Changes in BMI Associated with Improvements in Disease Activity & Glucocorticoid Treatment
A recent study examined the relationship between increased BMI and antineutrophil cytoplasmic antibody–associated vasculitis treatment with glucocorticoids. The results: Weight gain was independently associated with reductions in disease activity, increased glucocorticoid exposure and randomization to rituximab. The most significant increases in BMI occurred during the first six months of treatment, and newly diagnosed patients were more likely to experience an increase in BMI…
Being Active May Reduce Risk of Chronic Low Back Pain
(Reuters Health)—Regularly engaging in physical activity, from walking to intense exercise, may help to reduce the risk of chronic low back pain by, as much as 16%, according to a new review of previous studies. In the past, it hasn’t been clear whether physical activity staves off low back pain, or people without back pain…
Senate Republicans Unveil Obamacare Replacement Bill with Tough Debate Expected
WASHINGTON (Reuters)—U.S. Senate Republicans on Thursday unveiled their version of legislation that would replace Obamacare, proposing to kill a tax on the wealthy that pays for it and reduce aid to the poor to cut costs. With Democrats deeply opposed to Republican attempts to overhaul former President Barack Obama’s signature healthcare law, the route to…
- « Previous Page
- 1
- …
- 180
- 181
- 182
- 183
- 184
- …
- 323
- Next Page »